NSCLC SCLCAnlotinib's Efficacy and Safety in Later-Line Treatment of Driver Gene-Negative Advanced Metastatic Non-Small Cell Lung Cancer and Extensive-Stage Small Cell Lung Cancer

This study focuses on understanding the benefits of a drug called anlotinib for patients with advanced stages of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) that have not responded to previous treatments. Anlotinib is a multi-targeted anti-angiogenic tyrosine kinase inhibitor, which means it works by blocking the growth of new blood vessels that cancer cells need to grow and multiply. It has shown promise in treating advanced soft tissue sarcoma and is approved in China for second-line or later treatment. However, there is limited information on its effectiveness in treating NSCLC and SCLC after the disease has progressed following initial treatment. This study aims to fill this gap and potentially improve care for these patients. The study is retrospective and observational, meaning it looks back at data from patients who have already received anlotinib treatment. It seeks to evaluate the efficacy and safety of anlotinib, either as a standalone treatment or in combination with other therapies, in later-line treatment of NSCLC and SCLC. The primary outcome measured is Progression-Free Survival (PFS), which is the length of time during and after the treatment that a patient lives with the disease but it does not get worse.